Physician profile
Mark Edwin Perry
NPI 1942267414
$11,493.25
in general payments reported to CMS, 2019-2025
25 companies · $1,457 in 2025
The $1,457 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,726 · 2020: $511 · 2021: $1,612 · 2022: $1,257 · 2023: $1,552 · 2024: $2,377 · 2025: $1,457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,187 · Entertainment: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,187.33 |
| Entertainment | $199.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,637.56 | 2019-2025 | Dailies Total1, Precision 1, Total30 |
| Coopervision INC. | $2,341.69 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $2,095.91 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,912.91 | 2019-2021 | |
| Optos, INC. | $425.11 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Topcon Healthcare, INC. | $376.59 | 2021-2025 | |
| Lkc Technologies, INC. | $267.45 | 2024-2025 | |
| Lombart Brothers, INC. | $203.64 | 2024 | Opd-III |
| Optovue, INC. | $187.37 | 2019-2021 | |
| Maculogix, INC. | $152.58 | 2019 | |
| Astellas Pharma US INC | $145.47 | 2023 | |
| Amgen INC. | $122.35 | 2024 | Tepezza |
| Shire North American Group INC | $121.85 | 2019 | |
| Oyster Point Pharma, INC. | $108.49 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $79.98 | 2020-2025 | Cequa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $54.80 | 2024 | |
| Abbvie INC. | $53.34 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $46.85 | 2020-2022 | |
| Dompe US, INC. | $40.10 | 2024-2025 | Oxervate |
| Visionix USA, INC | $40.00 | 2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Allergan, INC. | $21.51 | 2022 | |
| Abb Con-Cise Optical Group LLC | $18.90 | 2019-2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.